Market Overview

Amgen Will Make Shareholder-friendly Moves In 2018, Argus Upgrades

Amgen Will Make Shareholder-friendly Moves In 2018, Argus Upgrades
Related AMGN
The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
Amgen Increases Quarterly Dividend (GuruFocus)

Amgen, Inc. (NASDAQ: AMGN) is likely to helped by both fundamental catalysts and the positive impact of the new U.S. tax law, an analyst said.

The Analyst

Argus analyst David Toung upgraded Amgen from Hold to Buy and set a price target of $220. In November, the firm had downgraded Amgen on concerns about slowing sales of its top three products.

The Thesis

Amgen will implement shareholder-friendly moves this year, using the cash it repatriates from overseas, valued at $39 billion, Toung said in a Tuesday note. The company is likely to use the cash for buybacks, dividend increases, as well as M&A and new drug development, Toung added.

The analyst also sees several fundamental catalysts for growth in 2018, the analyst said. The catalysts include label expansion for Rapatha to include cardiovascular benefits, and multiple myeloma drug Kyprolis, adding longer survival data to its label, the likely approval of its migraine drug Aimovig and the launch of new biosimilar products.

"We expect new product launches, along with larger addressable markets for existing drugs, to offset the slower growth of mature products in 2018," Argus said.

As such, the firm maintained its adjusted earnings per share estimates of $12.55 for 2017 and $12.80 for 2018. The firm also expects the company's guidance for 2018 to reflect the impact of the recent changes in the U.S. corporate tax rates.

Amgen is scheduled to release its fourth quarter results on Feb. 1.

The Price Action

Amgen shares are up about 11 percent over the past year.

In pre-market trading, shares were up 0.90 percent to $194.07.

Related Links:

Amgen Stock Falls After 'Boring' Q3 Beat

A Survey Of Celgene's M&A Strategy

Latest Ratings for AMGN

Nov 2018CitigroupMaintainsNeutralNeutral
Oct 2018Morgan StanleyMaintainsOverweightOverweight
Oct 2018Morgan StanleyMaintainsOverweightOverweight

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Argus David ToungAnalyst Color Upgrades Price Target Top Stories Analyst Ratings Best of Benzinga


Related Articles (AMGN)

View Comments and Join the Discussion!

Latest Ratings

BAPItau BBAUpgrades274.0
DVNJP MorganDowngrades37.0
EOGJP MorganUpgrades118.0
EXPDGoldman SachsDowngrades68.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Loonie Approaches Key Resistance Level Of C$1.2450

This Analyst's Bearish Stance On Lumentum No Longer Applies